Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike. Please watch the video at Investors.com - Biotech Stocks Are ...

including Eisai/Biogen’s approved therapy Leqembi (lecanemab) and Eli Lilly’s donanemab, which is currently under review by the FDA. AC Immune chief executive Dr Andrea Pfeiffer said the ABATE ...

Biogen has revealed encouraging phase 2 results ... of Nephrology (ASN), IgAN is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.

Biogen lifts annual profit forecast as new treatments boost earnings Starting on a more ... Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent ...

Viehbacher said Biogen also has late-stage studies underway with felzartamab in rare immune-related indications including kidney transplant patients and for experimental lupus drugs. "It is hard ...